Research on anal squamous cell carcinoma: Systemic therapy strategies for anal cancer

Ryan M. Carr, Zhaohui Jin, Joleen Hubbard

Research output: Contribution to journalReview articlepeer-review

Abstract

Anal squamous cell carcinoma (ASCC) is a rare malignancy, with most cases associated with human papilloma virus and an increased incidence in immunocompromised patients. Progress in management of ASCC has been limited not only due to its rarity, but also the associated lack of research funding and social stigma. Historically, standard of care for invasive ASCC has been highly morbid surgical resection, requiring a permanent colostomy. Surgery was associated with disease recurrence in approximately half of the patients. However, the use of chemotherapy (5-fluorouracil and mitomycin C) concomitantly with radiation in the 1970s resulted in disease regression, curing a subset of patients and sparing them from morbid surgery. Validation of the use of systemic therapy in prospective trials was not achieved until approximately 20 years later. In this review, advancements and shortcomings in the use of systemic therapy in the management of ASCC will be discussed. Not only will standard-of-care systemic therapies for locoregional and metastatic disease be reviewed, but the evolving role of novel treatment strategies such as immune checkpoint inhibitors, HPV-based vaccines, and molecularly targeted therapies will also be covered. While advances in ASCC treatment have remained largely incremental, with increased biological insight, an increasing number of promising systemic treatment modalities are being explored.

Original languageEnglish (US)
Article number2180
JournalCancers
Volume13
Issue number9
DOIs
StatePublished - May 1 2021

Keywords

  • Anal squamous cell carcinoma
  • Chemoradiotherapy
  • Human papillomavirus
  • Immunother-apy
  • MTOR
  • Papillomavirus vaccines
  • PI3K

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Research on anal squamous cell carcinoma: Systemic therapy strategies for anal cancer'. Together they form a unique fingerprint.

Cite this